Stock analysis for MorphoSys AG (MOR:Xetra) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of
MorphoSys AG shares opened the reporting year at a share price of € 48.75. After a volatile start in the first weeks of 2017, the shares marked their low for the year on February 6 at € 47.60. The shares then trended higher in line with the TecDAX before breaking out in September with price performance far outpacing the benchmark index.
Latest MorphoSys AG Share Price – Live MOR share price quotes, charts, profile, RNS & company financials for ETR:MOR. Focus on All Regions. BRIEF-Morphosys Says Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Ulcerative Colitis 12th Dec ’18
The current share price of MorphoSys is above its future cash flow value. Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth. PRICE RELATIVE TO MARKET
Quotes for MorphoSys Stock. Price 102.25 Day’s Range 100.40 – 102.50 Trade Time 04:00PM 52-week Range 56.44 – 124.70 Trade Date 08/23/2018 52-week Perf. The price of 102.25 EUR on the exchange Stuttgart equals a price of 118.17 USD at the current exchange rate for EUR/USD.
MorphoSys AG stock price, stock quotes and financial overviews from MarketWatch. MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.
U.S. Markets open in 4 hrs 15 mins. Novartis said on Thursday it will pay 95 million euros to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its
Discover historical prices for MOR stock on Yahoo Finance. View daily, weekly or monthly format back to when MorphoSys AG stock was issued.
MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.